

A Joint Biological and Microbiological Analysis of Immune and Cellular Responses to Pathogenic Microorganism

Wameedh Sabah Shukur

University of Al-Kut – College of Health and Medical Technologies Department of Aesthetic and laser technologies

Noor Al-Huda Lafteh Baid Hami

Al-Muthanna University College of Science Department of Biology

Safa Safaa Muneer Jassim

University of Tikrit college of Science Department of Biology

Received: 2025, 15, Oct

Accepted: 2025, 21, Nov

Published: 2025, 10, Dec

Copyright © 2025 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).



Open Access

<http://creativecommons.org/licenses/by/4.0/>

Annotation: Research on immunity and host-pathogen interactions spans an immense range of topics but can often be divided into biological and microbiological perspectives. Biological approaches centre on cellular and humoral responses, delineating factors such as signalling and immunometabolism that shape both effector responses and pathogen control. By contrast, microbiological approaches focus on the diversity of pathogens, their interaction with a given host, and the resulting host responses. Biologists have called for the micrometric complexity of pathogens and host-pathogen interactions to be integrated with the macroscopic physiology and cellular interactions considered in immunology. More broadly, compelling case studies illustrate the power and usefulness of joining biological and microbiological analyses.

Contemporary biologists emphasise

the universality of the immune system and its extraordinary capacity to adapt, while microbiologists highlight the immense variety of infecting pathogens and the consequent diversity of host responses. Just as biological concepts such as memory, amplification, and education are fundamental to microbiology, the extraordinary diversity of infecting agents and associated host responses has much to offer contemporary biology. Vaccination has been termed one of the great triumphs of science and is juxtaposed with cancer, antibiotic resistance, and emerging pathogens among the grand challenges for humankind.

1. Introduction

Infectious diseases are re-emerging as a major threat to global health security, with more than ten new pathogens having been identified in the last two decades. These too often deadly agents continue to be transported internationally. For infections to survive, virulent microbes have evolved diverse strategies [1]. A multitude of microorganisms classified as bacteria, viruses, fungi, or parasites have acquired intricate mechanisms of pathogenicity and evasion of the host's immune system. Pathogens leave an ecological footprint that inevitably produces damage at the population and species levels. Myriad microorganisms thus continually compete for dominance both intra- and inter-species, in cows, fish, humans, as well as in all living organisms.

Diverse surface receptors that can be classified as pathogen-associated molecular patterns widely exist to defend against a variety of dangerous pathogens. Other competing microorganisms adopt mechanisms that block and/or disable the perception of the detecting organism. Sequences of fighting pathogens can be modelled and large datasets generated to arrest the spread of viruses or mycobacteria among the host population. Two major repercussions are foreseen: during the infectious attack of the pathogen the host loses at least one basic material—sometimes a large amount—while the circulating signals tend to augment. From the immune system retro-fitting perspective, the pivotal vital point depends on how correctly and rapidly the host cell can recognize the invader after the pathogen hysteria is over. Effective recognition design will be matched with pathogen seeking through intra-cellular organelles.

The present analysis aims to survey the pathogens of diverse classes along with their cellular and immune strategies and responses; an outline of a tentative selection of essential common pathogen rules and responsive protocols in cellular and immune realms will also be provided to enrich the existing datasets of grand historical chronologies. [2][3][4]

2. Background and Rationale

The study of microorganisms of health importance has led to a fuller understanding of cellular and immune responses, and how these responses manifest in a host. The integration of microbiological

and biological approaches enhances this understanding. Pathogenic microorganisms can be defined as invasive microorganisms that cause infection and produce a wide variety of disease. Classification has traditionally separated organisms into bacteria, viruses, fungi, and parasites. Each of these four classes possesses general mechanisms of pathogenicity, although such generalization is not absolute. Pathogenic intermediate processes situated between a class of pathogens and the host may be identified. Virulence, or the relative ability of a pathogen to cause disease is not a required condition for parasitism. The terms infective dose or infectivity may better describe the general classification category of pathogens. Any unintentional process that impairs the health of a host might constitute infection. Some microbes are pathogenic because of their ability to remove iron from the host, an unfavourable agent whose exact developmental role is undecided.

In the case of organisms commonly regarded as non-pathogenic, protective roles of the normal microbiota in the genitourinary tract are disregarded. Pathogenicity of some organisms is either dependent on a specific host or is a secondary consequence of an opportunistic sequence initiated by freshwater exposure and submarine drilling. Engagement of the host and engagement of the pathogen should be seen as coupled events. Pathogenesis by viruses, fungi, and parasites constitutes the next level of cross-cutting. Bacteria have the most extensive exploration of pathogenicity mechanisms, such as the large growing area of host-pathogen interactions made sufficient precision and altruism possible. The most general concept of host-pathogen interaction includes the simultaneous presence of two interacting organisms in a determined geographic environment either factually or potentially opening a space for a complementary integration of biological and microbiological perspectives [1].

3. Pathogenic Microorganisms: Classification and Mechanisms

Pathogenic microorganisms cause diseases in humans, animals, and plants, relying on specific mechanisms of pathogenicity. Microbiologists classify pathogens into bacteria, viruses, fungi, and parasites. Despite differences, shared pathogenic mechanisms include attachment and colonization, nutrient acquisition, evasion of host defenses, tissue damage, and dissemination throughout the host. Co-infection with different pathogen types is often observed, with evolution-driven networks underlying shared pathogenic traits among distinct pathogens.

Bacteria possess unique attributes that enable disease development. Virulence factors are produced to resist innate and adaptive immunity and enhance damage. Pathogenic bacteria deter phagocyte chemotaxis, induce destructive inflammation, inhibit phagocytosis, secrete toxins, and damage tissues. Defense against bacteria involves physical barriers, secreted antimicrobial factors, phagocytic cellular immunity, and complement-mediated clearance.

Viruses can access diverse cellular compartments via numerous entry mechanisms. Viral persistence in the host depends on mutation, latency, and spread to immune-privileged sites. Autophagy and RNA interference act as antiviral defenses, while innate and adaptive immune responses recognize viral structures and products. Fungi cause disease through functionally independent immune pathways. Pathogenic niches encompass internal and external body sites. Fungal toll-like receptors recognize conserved patterns on fungal surfaces, whereas Galectins and Dectin-1 capture fungi for Th17 and Th1 cellular responses.

Parasites undergo defined cycles involving various hosts. The host's primary immune responses shape parasite survival or replication. Immune evasion through polymorphism, protein secretion, and immunosuppressive factors influences the dynamics between parasites and their hosts. [5][6][7]

3.1. Bacteria

Pathogenic bacteria are defined as bacteria capable of inducing damage to the host and causing disease. These organisms exhibit a range of traits that support their virulence, which has extensively been studied by Koch and Pasteur. In contrast to these traits, it is also possible to

define the general properties of microbial pathogens and the interactions between the host and the pathogen. The innate immune response may first be divided between the global signals that indicate the pathogen and the specific mechanisms that either control dissemination to the deeper tissues or directly destroy the pathogen. Many bacteria therefore replicate in the cytosol or vesicles before altering the immune response that they trigger. Others, especially during the acute, encounter rapidly feed-back circuits are established and target the very entry step of the microorganism during the early phase of the infection. More than 280 bacterial species are pathogenic to humans and can cause infectious diseases, including those marked coffin tissues.

Pathogens can be grouped into classical categories: bacteria, fungi, protozoa, helminths, and viruses, but this classification does not address how they interact with the host. Therefore the mechanisms of pathogenicity and host interactions are highlighted across groups. Importantly viruses are obligate intracellular pathogens, they can enter cells passing through physical and molecular resistors. The commonalities of entry strategies performed by these agents have shaped these large-scale answers, making both fundamental processes and specific select. Bacteria are typically considered as non-eukaryotic parasites and tend to occupy extracellular niche. Fungi are eukaryotic pathogens which exhibit non-intrusive saprophytic adaptability. Forms of eukaryotic pathogens and parasitic agents, with a proportion of the life cycle free in extracellular environments. Since they can reside in much deeper and more varied host sites, eukaryote parasites tend to create much more complex, tightly-measured or poorly-measured forms of care. [8][9][10]

3.2. Viruses

Different viruses exploit distinct strategies to enter cells, replicate, and exit the host. Viral particles are made of nucleic acid (DNA or RNA) surrounded by a capsid, which gives the particle shape and aids attachment to host cells. Some viruses acquire a lipid envelope derived from the host cell during replication, while others remain non-enveloped. The lipid envelope usually contains glycoproteins that serve as ligands for specific cell-surface receptors, and binding of the virus to its receptor is the main mechanism for viral entry; many cellular receptors are also involved in cellular functions. After entry, enveloped viruses often follow a route similar to that of host cell endosomes, while non-enveloped viruses can enter through non-receptor-mediated endocytosis, clathrin-independent endocytosis, micropinocytosis, and membrane penetration.

Once in the cytoplasm, viruses utilize cell-provided translation machinery to direct the synthesis of viral proteins and genomes. Some viruses enter the nucleus for genome replication and transcription, relying on host polymerases, while others execute these events within the cytoplasm, using viral RNA polymerases. Reassembled viral components produce new virions, which can be released by lysis of the host, low levels of cellular exocytosis, or budding through the plasma membrane or cell organelle membranes. All exposed cells, particularly epithelial surfaces, should be able to sense virus infections and respond rapidly to mitigate virulence. Cellular recognition depends not only on pattern recognition receptors but also on detection of unique viral glycosylation patterns. The innate response to viruses relies on several complementary mechanisms that sense, control, and eliminate infections. Monocytes, macrophages, and dendritic cells coordinate viral-induced type I interferons, proinflammatory cytokines, and chemokines, and the presentation of antigens to adaptive effector cells. Memory T and B cells provide virus-specific CD4+, CD8+, and neutralizing antibodies that represent the most effective clearance strategy. [11][12][13]

3.3. Fungi

Adaptive and innate immune systems recognize fungal pathogens, triggering Th1 and Th17 responses that help control infection. Neutralizing antibodies mark fungi for removal, but their role is less clear than for viruses and bacteria. Dysregulation can lead to asthma and other diseases. Some fungi, like *Candida* spp., exist in healthy individuals but remain dormant; they cause disease only when barriers are compromised. Other fungi, like *Histoplasma* or *Coccidioides*,

are inhaled but produce endemic disease in susceptible hosts.

The distinctive cell wall of fungal pathogens, combined with the expression of virulence factors, governs the host–fungus relationship and participates in innate immune detection. Chitin, β -glucans, mannan, and phospholipomannan constitute the main components of the cell wall and interact with host pattern recognition receptors. The detection of fungal pathogens triggers the production of proinflammatory cytokines, chemokines, and lipid mediators, which in turn recruits neutrophils and macrophages to the site of infection. The interplay between neutrophils and macrophages also directs the differentiation of Th1 and Th17 cells, which subsequently activate CD8+ and effector memory T cells.

Fungi also modulate the host immune response to promote their survival and persistence within the host. These observations emphasize the need for a proper immune response during fungal infection, as aberrant activation or downregulation of protective elements can lead to different clinical manifestations. [14][15]

3.4. Parasites

Infectivity and virulence are intimately linked to the parasite life cycle, which encompasses at least two different life stages that alternate between intermediate (often invertebrate) and definitive (usually vertebrate) hosts [16]. These different life stages require major metabolic, antigenic, and developmental changes that can complicate the host-parasite relationship. Parasites can evade host immunity through complex life cycles requiring passage through different hosts [17]. A parasite's preferred niche depends not only on its life history but also on tissue properties and associated immune responses. The immune system has evolved multiple mechanisms to respond to simultaneously active parasites through locally coordinated responses at the sites of infection and against secondary parasites further distributed throughout the host. Many helminths exhibit low antigenic variability and can counteract host immunity by indirect means such as modifying the functions of affected cells and tissues. Evasion and modulation mechanisms include excretion of lipid mediators, and any cells exposed to helminth products tend to drive the immune response towards Th2. [18][19]

4. Innate Immune Responses to Pathogens

Pathogens maintain their extraordinary ability to exploit host cells and cause disease despite the collective sophistication of the immune system, and the host often lives uneasily with the infectious agent. Pathogenic microorganisms can be classified into four major groups: bacteria, viruses, fungi, and parasites. Broadly conserved pathogenic mechanisms and host-pathogen interactions characterize these groups.

Bacteria

Bacteria are unicellular prokaryotes without membrane-bound organelles. They have a variety of morphologies and multiple pathways for energy acquisition—some are motile, and all have the capacity to grow rapidly under optimal conditions. Pathogenic bacteria such as *Mycobacterium tuberculosis*, *Escherichia coli*, and *Listeria monocytogenes* exploit their structural and growth characteristics in specific ways to infect and survive within the host. In addition to these group-characteristic traits, specific virulence factors such as exotoxins, endotoxin, capsules, secretion systems, and iron-scavenging systems further influence bacterial pathogenicity. The bacteria also induce a broad array of host responses, ranging from cytotoxic effects to the production of proinflammatory cytokines and chemokines. These diverse traits underscore the importance of examining the immune system at a level that encompasses all studied pathogens.

Viruses

Viruses are acellular obligate intracellular parasites that consist of a genome within a protein coat (capsid); a subset of viruses is also enveloped. They replicate by commandeering the host cell's translational and transcriptional machinery. Viruses exploit multiple entry pathways, including

direct fusion of the viral genome with the host plasma membrane, endocytosis of an enveloped virus followed by fusion at an endosomal membrane, nuclear pore transport, and injection of the genome through the bacterial cell wall. Following cellular entry, the genome is uncoated, and replication occurs. If the viral genome is DNA based, it may be rapidly integrated into the host genome via enzyme(s) encoded in the viral genome. In the case of DNA viruses such as adenovirus, replication occurs in the nucleus, while for RNA viruses such as rabies virus, flavivirus, and poliovirus, replication occurs exclusively in the cytoplasm. Soon after entry, the host can detect the virus, leading to the induction of proinflammatory cytokines and interferons that establish an antiviral state. In turn, the virus may some interfere directly with the host detection system, for example, through proteosomal degradation [20].

Fungi

Fungi represent a large and diverse group of eukaryotic organisms, ranging from simple unicellular yeasts to complex multicellular pathogens. Approximately 300 species are capable of causing disease in humans, yet only 50 are responsible for the majority of human infections; although fungi are eukaryotes similar to mammalian cells, they remain a serious threat to the immunocompromised. Fungal pathogens can inhabit distinct niches within the immune-competent mammalian host and exhibit opportunistic behaviour, yet those capable of infecting healthy individuals are responsible for the majority of life-threatening cases. Opportunistic fungi such as *Candida albicans* and *Aspergillus fumigatus* primarily exploit barriers to colonisation for establishment; by contrast, *Histoplasma capsulatum*, *Coccidioides immitis*, and other endemic mycoses occupy the lungs as a site of initial infection, necessitating regulated dimensional transition from yeast to mycelium. Fungi present a complex evolutionary mosaic of immune recognition patterns across class, phylum, and kingdom, yet experimentally-defined signatures can be consistently identified. Different immune care considerations are required for these taxa, complicating therapeutic decisions for fungal infections. Despite highly conserved virulence traits, fungal pathogens exhibit an extraordinary breadth of adaptive responses and interactions with the mammalian immune system. [21][22][23]

Parasites

Parasites exhibit complex life cycles with one or more stages in which they inhabit and exploit the host. Pathogen life cycles, modes of immune evasion, and host-pathogen dynamics vary substantially across the taxa; acquired immunity plays a key role in the clearance of several pathogens throughout the vertebrate body.

Parasitic worms (helminths), which are multicellular eukaryotes, are capable of infecting the gastrointestinal tract, skin, lungs, veins, heart, muscle, or central nervous system. These pathogens arose early in eukaryotic evolution and continue to scour these phylogenetically-preferential niches, complicating immune defence and providing selectively-advantageous system-specific immune modulations in the closely-related invertebrate host. *Trichuris muris* establishes a cryptic and persistent infection in the rodent gastrointestinal tract; the worm sheds eggs that escape innate immune recognition and develop an orally-viable larva. Concurrently, nematodes such as *Heligmosomoides polygrus* and *Strongyloides ratti* exploit their excretory-secretory product (ESP)-blooming lifecycle at the dermis to hijack the Th2-dominant immunity induced by *T. muris* infection.

Protozoan infections from vector groups such as mosquitoes, tsetse flies, and sandflies are also important global parasites. The protozoan parasites of the *Plasmodium* species have a complex life-cycle involving two hosts, specifically, mammalian or avian blood-fed invertebrates, as well as the salivary gland of the vector. In mammals, the parasites have been observed to infect the liver and red blood cells. In preliminary studies on infection dynamics in mice, the *Plasmodium* life-cycle appears to be 48 hours for the mammalian cycle, and addressing the dynamics with the successive host cells at a fine time-scale is crucial for understanding the productive infection and corresponding immunities. Observations from the malaria studies and other mammals strongly

indicate that both MHC class I and class II are involved during the first infection for stages involving sporozoite and infected liver stages, and the MHC class I dynamics observed experimentally with the interaction of hepatitis is complementary to the existing knowledge. [24][25][26]

4.1. Physical and Chemical Barriers

The skin plays a crucial role in protecting against invading microorganisms. These organisms penetrate epithelial layers to cause infection. Embedded in the epithelial layers, skin-associated immune cells play an active role in sensing the entry of microbial pathogens. Regulating immune sensors is, therefore, crucial for maintaining immunity.

Microorganisms constantly invade the host, exposing it to a myriad of harmful agents from the external environment. Pathogenic infections can exist as bacteria, viruses, fungi, and parasites. Pathogenic bacteria can be classified by their physiology (Gram staining, spore formation) or according to their morphology (cocci, bacilli, and helical). Microbial pathogenesis may be detected through bacterial-induced wound models.

Pathogenic bacteria can be classified into two groups according to the way they propagate (biopolar versus unipolar) and can be further categorized according to their characteristics. Ability to utilize host nutrients is a trait shared by many pathogenic bacteria, resulting in rapid growth which in turn increases bacterial virulence. Intracellular viruses can invade and replicate within endothelial, epithelial, and other cells. Pathogenic fungi exist as yeast or mould at the temperature of the environment while sphere-shaped micro-organisms (yeast) are detected when infecting the mammalian host. The parasitic life style of these micro-organisms is complex and some may escape therapeutic measures. [27][28]

4.2. Innate Immune Sensing

The innate immune system rapidly detects invading pathogens through germline-encoded pattern recognition receptors (PRRs) that identify conserved features of pathogens called pathogen-associated molecular patterns (PAMPs) and tissue damage-associated molecular patterns (DAMPs). Two principal families of PRR are Toll-like receptors (TLRs) and C-type lectin receptors (CLRs). TLRs recognize a variety of ligands found on different groups of pathogens: for example, fungal and bacterial cell wall components, flagellin, bacterial DNA, and viral RNA and DNA. While TLRs are primarily expressed on professional immune cells, such as dendritic cells (DCs), macrophages, and neutrophils, CLRs are mainly expressed on cells that encounter fungi, such as DCs and macrophages. Recognizing the wide range of PAMPs and DAMPs, both TLR and CLR signaling pathways activate proinflammatory responses via the release of proinflammatory cytokines—including tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-8, and IL-12—and chemokines that serve as chemotactic factors for immune cells.

Chemokine receptors, belonging to the G protein-coupled receptor family, orchestrate the movement of immune cells from the blood, lymph, and surrounding tissues to the site of infection by a process called chemotaxis. In addition to initiating a robust inflammatory response, PRR signaling influences the subsequent adaptive immune response. Activation of DCs, the main antigen-presenting cells linking the innate and adaptive immune systems, is critical for shaping the T helper cell responses that dictate the subsequent antibody isotype switched by B cells or cytotoxic T cell responses against intracellular pathogens. The importance of PRR signaling in driving adaptive immunity is supported by studies showing that immunization with protein-based vaccines in mice lacking TLRs or CLRs has diminished immunogenicity. Pathogen-specific T cell responses can also be enhanced or skewed by using adjuvants that target PRRs. [29][30][31]

4.3. Phagocytes and Antimicrobial Mechanisms

Neutrophils, macrophages, and dendritic cells are the main phagocytes involved in the innate immune response. Neutrophils respond rapidly and cooperate with other immune cells. They kill

pathogens through phagocytosis or by releasing granules containing reactive oxygen species and other bactericidins into the extracellular space. Macrophages can enter tissues from the blood or be recruited from monocytes. They are important for pathogen clearance, wound healing, and the induction of adaptive responses. Dendritic cells, which reside in tissues, detect pathogens through their pattern recognition receptors and transport infectious agents to draining lymph nodes, where they trigger adaptive responses.

Phagocytosis is one of the most efficient mechanisms for clearing pathogens. Phagocytes recognize and adhere to particles through pattern recognition receptors, which recognize pathogen-associated molecular patterns. After recognition, the particle is internalized, resulting in the formation of a phagosome. The acquisition of intracellular killing capacity starts with the fusion of the phagosome with a lysosome. The phagolysosome is then equipped with reactive oxygen species, reactive nitrogen species, antimicrobial peptides, and hydrolytic enzymes that degrade macromolecules inside the phagosome. These antimicrobial effectors are delivered via granules that fuse with the phagolysosome membrane or released into the extracellular space. Neutrophils also perform neutrophil extracellular trap formation, in which the activation of the nuclear enzyme, nicotinamide adenine dinucleotide phosphate oxidase culminates in the formation of neutrophil extracellular traps. These traps consist of chromatin and are decorated with bactericidal proteins, allowing them to entrap and kill pathogens. [32][33][34][35]

4.4. Complement System

Every exposed surface of the body, especially areas that are wet and exposed to environmental challenges, is a possible entry point for pathogens. However, organisms are protected against colonization by a variety of physical barriers. These include the skin and mucosal surfaces of the respiratory, gastro-intestinal, and uro-genital tracts. These barriers are chemically reinforced by secreted substances (e.g. lysozyme in tears, defensins on skin and mucosal surfaces, in saliva and in the lungs) and by both inhibitory and anti-microbial soluble factors in the serous fluids. In addition to the above mentioned factors, the complement system contributes to the innate immune protection against invading pathogens.

The complement system is a component of the innate immune system that detects pathogens through triggering systems of soluble pattern recognition receptors and ultimately supports pathogen elimination by different means including opsonization, inflammation and pathogen lysis. In humans, complement is composed of more than 40 soluble proteins and it is mainly produced and secreted by the liver. Activation of the complement system can occur via three different pathways: the classical pathway (activated through binding to antibodies), the lectin pathway (triggered by binding of lectin to specific carbohydrates of the pathogen) and the alternative pathway (spontaneous). The recognition of pathogens by conserved surface patterns is essential for self-nonself discrimination. Recognition promotes pathogen opsonization, a process whereby the pathogen is coated by small soluble molecules that facilitate recognition and internalization. The main opsonins are C3b and IgG. C3b opsonizes a variety of pathogens but its activity is reinforced by the presence of specific receptors in phagocytes; IgG is also recognized by specific receptors present in all cells of the immune system. The complement system also participates in inflammation-mediated pathogen elimination and, in the case of Gram-negative bacteria, catalyzes the lysis of the pathogen. [36][37][38]

5. Adaptive Immune Responses and Specificity

Adaptive immune responses to pathogenic microorganisms are initiated when the innate pattern-recognition receptors (PRRs), such as Toll-like receptors, do not clear the pathogen. These responses are more effective than the innate ones against intracellular pathogens; they can target particles that have evaded multi-faceted innate immune recognition. B lymphocytes and T lymphocytes play an essential role in adaptive immunity. These cells express antigen receptors that recognise and bind to variants of proteins. The large diversity of receptors is generated from a limited number of gene segments. The cellular communications required by adaptive immune

responses are subservient to the on-off relays and frequency-modulation of PRR signalling [39]. B lymphocytes can be activated further by T lymphocytes to form germinal centres in secondary lymphoid organs. Throughout the development and evolution of an immune response, high mutation rates in antigen receptor-encoding genes drive the increase of mutation thresholds in cognate genes, allowing receptors to exhibit cross-reactivity patterns similar to those observed in evolution [40]. The evolution of high mutation rates in the genome of a competing pathogen has effects the other way round. Pathogen-driven adaptations commence locally, and the immune response simultaneously partitions into two branches that rewrite the adaptive history of the pathogen, thereby inducing pathogen strain diversity [41].

5.1. Humoral Immunity and Antibody-Mediated Neutralization

Antibodies are highly specific proteins of the immunoglobulin superfamily produced by the adaptive immune system in response to antigen. In the course of an immune response, multiple classes of antibodies with different effector functions are produced, ranging from IgM, which is mainly responsible for complement fixation, to IgA and IgG, which are specialized for neutralization. Antibodies are secreted into mucosal, skin, and serum compartments, where they exert their protective function by blocking pathogens from entering the host, neutralizing toxins, and marking pathogens for clearance by other cells.

B lymphocytes are required for serological or humoral immunity, whereas serological memory following natural infection or vaccination is conferred largely by serological IgG and/or IgA. Prior exposure to a specific pathogen or vaccination schedule induces a second wave of affinity maturation through somatic hypermutation, resulting in higher affinity serum antibodies. Simple binding is not sufficient to achieve protection; neutralizing antibodies must recognize antigen in a neutralizing conformation and block the relevant step in viral entry or exit.

Generally, neutralization requires a relatively high titer (>100-fold over half maximal effective concentration of virus) and is of relatively low affinity ($KD > 100$ nM), although notable exceptions exist for rotavirus. Neutralization can be confirmed using pseudoviruses or live attenuated strains in convalescent serum samples lacking detectable neutralizing activity. Prior exposure to other viruses that use the same cellular receptor or that share structural features with a given pathogen can influence antibody specificity through extensive cross-reactivity. Subsequent viral infections can also engender a poorly contained form of serological memory known as heterologous immunity, which may offer limited protection against a different strain of the same virus, although vaccine-induced control of other viral strains is much stronger and associated with broader-specificity antibodies. [42][43][44]

5.2. Cellular Immunity: T Lymphocytes

Lymphocytes are the most important cell type of the adaptive immune response. Two different groups of mature T lymphocytes, CD4⁺ and CD8⁺ cell populations, exert distinct but complementary functions. Both subtypes are activated by specific antigens presented on major histocompatibility complex (MHC) molecules of antigen-presenting cells (APCs). The antigen-specific CD4⁺ T lymphocytes are crucial for orchestrating the adaptive immune response; they provide help for B lymphocytes and CD8⁺ T cells and activate phagocytes, such as macrophages, to eliminate intracellular pathogens and regulate innate immune responses. MHC class II molecules present extracellular antigens that were taken up by professional APCs and processed into peptides. The peptide–MHC class II complexes are recognized by the T cell receptor (TCR) on CD4⁺ T cells, and their activation leads to differentiation into T helper 1 (TH1), TH2, TH17, or T follicular helper (TFH) cells, depending on the type of immune response required. In contrast, naive CD8⁺ T cells differentiate into cytotoxic T lymphocytes that eliminate virally infected cells and cells harboring intracellular pathogens. The TCR recognizes peptides presented on MHC class I molecules, which are expressed by all nucleated cells, enabling the recognition of aberrant cells through the presentation of endogenous antigens. Activation of CD8⁺ T cells is aided by CD4⁺ T cells. Memory CD4⁺ and CD8⁺ T cells provide rapid recall responses upon reencountering the

same antigen.

Antigen uptake is a crucial process for the activation of T lymphocytes. TCRs recognize MHC-peptide complexes, and these complexes have low affinities for the TCRs. Therefore, professional APCs express several integral membrane proteins that facilitate T lymphocyte activation. These proteins include adhesion molecules that promote localization of neutrophils at sites of inflammation, costimulatory molecules, and members of the B7 family of proteins. In addition to T lymphocyte activation, CD4⁺ T lymphocytes perform several helper functions, including supporting the activation of B cells, promoting the cytotoxic activity of CD8⁺ T cells, and activating phagocytes that eliminate pathogens. These types of T cell responses provide protection against different types of pathogens. [45][46][47]

5.3. MHC and Antigen Presentation

Major histocompatibility complex (MHC) restriction, introduced by Doherty and Zinkernagel, describes the simultaneous requirement for an epitope, as a processed peptide, to bind to MHC, and a T cell receptor (TCR) on the T cell [48]. Antigen presentation relies on the uptake of antigens by antigen-presenting cells (APCs). The antigen is processed by proteolytic degradation within endosomal, lysosomal, or cytosolic compartments, liberated from its carrier protein, and presented as a peptide bound to MHC molecules on the APC surface. Classically, two distinct pathways are recognized: the MHC class I pathway for cytosolic antigens and the MHC class II pathway for extracellular antigens. Antigen source dictates the processing pathway and stream of presenting MHC molecules, whereas the type of pathogen and signalling influence the encoding and acquisition of immunogenicity in the compromised antigen.

6. Cellular Signaling and Immunometabolism in Infection

Structural and functional mechanisms underlie firm host-pathogen attachment and invasion and influence subsequent immune responses—key determinants of pathogenicity [49]. Bacteria, viruses, fungi, and parasites exploit diverse invasins and exoenzymes to bypass extracellular barriers and enter the body, although considerable diversity in entry routes, transit, growth, and immune evasion exists [50]. Pathogen-oriented integration of biological and microbiological knowledge enables finer characterizations of particularly prevalent, emergent, and/or threatening agents, delineation of major immune control strategies, and identification of novel therapeutic candidates.

6.1. Cytokine Networks

In mammals, the immune system functions to prevent infections and other pathologies. It detects pathogenic microorganisms and maintains tolerance to commensal flora and self-structures. One of the major components of the immune system is the production of soluble factors, the cytokines, which are released in both basal and inflammatory conditions. Many cellular and physiological processes rely on the establishment of networks of these signaling factors, mediating the effects that the host can exert on the pathogen and on the progression of an ongoing infection. Cytokine networks are thus critical to understanding how the immune system works and what may be done to intervene [51].

6.2. Metabolic Reprogramming During Infection

During infection, immune cells undergo metabolic shifts that can enhance pathogen clearance [50]. Energy and specific biosynthetic pathways may be prioritized to mount a rapid immune response, overcome inflammatory stimuli, or establish long-lived immune memory. Such metabolic activity is coupled with transitions in immune cell activation states from naïve to effector, and to resting or memory. Early transcriptional responses identified at a single-cell level reflect distinct strategies for dampening or sustaining activity in T cells and other leukocytes that share metabolic dependencies.

7. Host-Pathogen Interactions: Case Studies

With their distinct biology and lifestyles, pathogenic microorganisms interact with the host and induce immune responses in multifarious ways. Diverse bacteria exemplify these interactions and the corresponding responses, ranging from pore-forming toxins to effector proteins delivered into the cytosol. The analysis of host-pathogen interaction of viruses reveals evolutionary strategies for avoiding detection and accelerating infection. Immune recognition of fungi in the oral cavity and other environments is often ambiguous, with a need to specify specific indicators. Lastly, parasites constitute a distinct group in need of specific insights.

Pathogenic microorganisms efficiently deploy multifarious mechanisms to modulate host-cell functions in pursuit of infection or replication. Bacteria employ sheath contraction to convert socially travelling signal into intracellular gene activation without prior receptor-activation. Subsequent surf-hop reactivation via pheromone delivery forms biofilm without resensing the environment, elaborating signalling in population-dense environments. Bacterial effector delivery enables extensive cytosolic remodelling for intracellular persistence under lethal dose, whereas cytosolic location affords access to host-shared resources for rapid genome diversification. Pathogen-host dialogues encompass both superficial competition and deeper microbiome-like synergetic collaboration.

Bacteria interact differently with host cells to evade and disrupt immune responses. Lengthy temporary engagement to internally extract sec-system substrates delays host-target infiltration. Preventing cytosolic access inhibits interactions with nuclear substrates, restricts transcription, and deters signal-nourishing cooperation. Viral-pathogen interaction occurring at multiple levels elicits sophisticated defence yet simultaneously refines detection to apply discernable selective pressures for engineered immune-evasion circuitry. Pathogen detection potentates protective response while inadvertently signalling to turn on and promote selective-pressures for suppressive code designed to circumvent said detection. Immune recognition is thus contingent on the interplay of competing insulator and discerner mechanisms. Fungi display physiologically-induced, communal-spread-transcriptional oscillations across cell-cycles and environmental cues allowing records of adjacent metabolic state and nutrient gains to be written jointly and reaccessed or reprogrammed locally. [52][53][54]

7.1. Bacterial Pathogens

Bacterial pathogens constitute the largest and most diverse group of infectious microbes, with the ability to live in every environmental or ecological niche on Earth. Their colonization into human hosts represents both an opportunity and a significant threat. Pathogenic bacteria utilize a range of virulence factors, which enable their entry, dissemination, and survival within a host. Pathogenic bacteria have developed various strategies to target every tissue in the host body. During infection, the host employs pattern recognition receptors (PRRs) to detect these opportunistic pathogens.

Host immune responses are similar to those of mice infected with the Gram-positive bacterium *Listeria monocytogenes*, the Gram-negative bacterium *Burkholderia pseudomallei*, or the Gram-negative bacterium *Salmonella enterica* serovar Typhimurium. The induction of type I interferon (IFN-I) and expression of double-stranded RNA (dsRNA)-sensing cytosolic sensors elevate stages of bacterial infection by altering host gene and protein expression patterns. The expression of antiviral genes by *Staphylococcus aureus* infection, and the subsequent induction of cellular sno-miRNAs by *Burkholderia pseudomallei* infection, result in various effects on host gene expression. Measurement of host-pathogen interactions during bacterial infections remains paramount for vaccine and therapeutic development [55].

7.2. Viral Pathogens

Viral pathogens are intracellular organisms consisting of genome coated with protective proteins. Viral infections can provoke a wide range of immune reactions before the elimination of virus and infected cells. Appropriately controlled infections offer protection from reinfections by

stimulating long-term immunological memory. Viruses are classified as acute or chronic depending on their survival strategies. Acute viruses undergo cell lysis, inducing a vigorous response for virus clearance but damage to multiple tissues. Structural proteins released during lysis trigger innate and adaptive immunity. The rapid replication of acute viruses enables the host to wait for weeks after clearance. Chronic viruses enter a post-replicative and non-cytolytic phase, exhibiting cyclical production without major lesions and persist for months to years to life. Even after the clearance of chronic viruses, anti-viral immunity may remain by inducing exceptionally durable immune memories. Interaction between these virus strains and viral immunity became a main focus of recent studies [56].

Viruses can enter host cells by binding to cell-surface proteins, and the majority of viruses depend on cellular mechanisms, such as membrane fusion, endocytosis, and nuclear transport, for their entry. Intracellular viral sensing is essential for appropriate immune response. Activating signals are transduced within the cell by two principal mechanisms: detection of cytoplasmic nucleic acid, typically through pattern-recognition receptors. Epitopes derived from the virion are packaged with MHC molecules, which are then delivered to the cell surface, supporting the CD8 T-cell elimination of viral infection. Depending on the virus, some cells can also instruct the CD4 T-cell expansion by displaying an exogenous antigen to CD4 T-cell, which secondarily improve CD8 T-cell responses.

7.3. Fungal and Parasitic Pathogens

Many pathogenic fungi produce inert structures that impede detection. Opportunistic fungi such as *Aspergillus*, *Candida*, and *Cryptococcus* pose serious threats to immune-deficient individuals. Diseases called mycoses range from respiratory infections to cutaneous lesions and meningitis. *Mucormycotina* fungi can cause life-threatening infections of the brain, sinuses, and lungs. *Dermatophytes* cause superficial infections of skin, nails, and hair. Organ transplants, anticancer therapies, and other medical procedures that immunosuppress the host increase susceptibility to opportunistic fungal pathogens. Climate change enables fungi to colonize previously inhospitable regions and may allow them to overcome mammalian body-temperature barriers, heightening risks for emergence and zoonosis [57].

Infections by parasites capable of extensive immune modulation are also particularly challenging. Stable reservoirs in macrophages, dendritic cells, and monocytes exploit vectors such as mosquitoes, sandflies, and tsetse flies; cyst forms persist in liver, muscle, and other tissues. Minimal exposure during secondary transmission keeps parasites below effective threshold levels. Active, chronic infections can be masked by substantial antigenic variation or by production of protective surface antigens also expressed by host cells. During schistosomiasis, extreme responses to excretory products of unrecognized foreign eggs trigger acute pulmonary syndromes, while chronic stages elicit Th2-polarized responses that amplify fertilization and transmission through vector feces.

8. Experimental Approaches in Immune and Cellular Analyses

Host-pathogen interactions can be studied using several complementary experimental approaches. The widely used in vitro cell culture model enables the analysis of food-borne pathogens, intracellular pathogens such as viruses and bacteria, and opportunistic pathogens, while controlling crucial parameters such as time, dose, and specific microbial components [58]. Animal models allow the investigation of the interaction of diverse pathogens with the host immune system. The chicken is an ideal model for studying vaccination, the bacterium *Salmonella enterica* serovar Typhimurium, and viruses such as Avian Influenza Virus, Marek's Disease Virus, Duck Hepatitis Virus, and Newcastle Disease Virus [59]. Mice are frequently used to study eukaryotic microbes (parasites) such as *Toxoplasma gondii*, fungal or protozoan pathogens, and viruses that infect mammalian cells (T. Adamo et al., 2023). Omics technologies such as transcriptomics, proteomics, metabolomics, lipidomics, and microbiomics provide straight-going data on the response of immune cells to diverse pathogens, pathogenic products, and vaccine formulations.

Microscopy is particularly valuable for visualizing immune cells, pathogen load, and infection dynamics in biologically relevant conditions. Multimodal imaging technologies can capture the spatiotemporal dynamics of the immune system (on individual cells) and cellular interactions (among multiple cell types) at various scales (cell-to-cell and tissue-level) with unprecedented resolution.

8.1. In Vitro Models

Immune response assessments targeting clinical infections often rely on in vivo analyses that pose ethical hurdles, inherent species differences, or translatability concerns. In vitro systems mitigate such limitations while enabling in-depth identification of host-pathogen engagements. Continuous advances in cell cultures, co-cultures, organoids, and microfluidic systems facilitate multilayer modelling of imminent complications, from human commensals and food-borne pathogens to airborne viral threats, bacteria, and fungi on gut, lung, and skin interfaces [60] ; [61] ; [62].

8.2. In Vivo Models

Experimental and theoretical approaches are essential to comprehensively investigate the host-pathogen interaction and the induced immune response. In vivo studies allow the exploration of local and systemic immune responses, as well as the effects of pharmacological interventions within a living organism. The benefits and limitations of in vivo approaches apply to experimental models that differ in complexity, ranging from simple insect models to large mammals.

Murine models are among the most widely utilized to study host-pathogen interactions and induced immune responses. They offer the advantage of extensive historical knowledge of their immunology and allow the study of individual-cell interactions using advanced imaging techniques such as multiphoton microscopy. Zebrafish and fruit flies present alternative in vivo models for the analysis of host-pathogen interactions. Automated time-lapse imaging systems with minimal perturbation of the host environment enable detailed spatio-temporal tracking of host and pathogen dynamics. In zebrafish, it is possible to observe immune responses and even substitution of key immune components. These models enable rapid screening of both pathogens and therapeutic compounds.

Apart from experimental considerations, in vivo approaches pose fundamental ethical issues. Agencies across the EU and the USA regulate live-animal experiments, and mass spectrometry represents a promising alternative that does not make use of living hosts. In silico modelling constitutes an additional alternative that can be applied alone or integrated with experimental analysis. Systematic identification of the governing biological mechanisms and their mathematical description provide a theoretical framework for the system under study. Mechanistic descriptions can be obtained by careful direct observation of the process and detailed analysis of relevant data.

Mathematical modelling helps to elucidate host-pathogen interactions and their management by the immune system using experimental data. A model of *Vibrio cholerae* infection has demonstrated the need for the presence of two distinct immune-cell types to capture the pertinent infection features. The distribution of immune cells has an important effect in shaping the immune response. A system model of *Bacillus cereus* infection includes both immune-cell recruitment and clearance processes, along with additional dynamics. Another modelling effort has successfully integrated the cell culture and organ-level systems of herpes simplex virus type 1 with the signalling pathways controlling the immune response. This strategy allows investigation of growth and immune-response regulation in a well-controlled organ environment. A modelling framework captures the dynamic interactions between *Salmonella enterica* and various immune-cell types in liver tissue and describes the effect of the bacterium on the immune response.

8.3. Omics and Imaging Techniques

Cells respond to a substantial variety of pathogenic microorganisms and several layers of immune

responses have evolved to counteract infection. In-depth characterisation of specific host-cell responses towards respective pathogens is an important step to better understand host–pathogen interactions and to evaluate the efficacy of new drugs or vaccines. Various methodologies, ranging from culture-inherent assay to high-throughput transcriptomic profiling, have been established towards analysing these interactions.

In vitro approaches using cell lines or primary cells present a powerful and flexible tool to investigate immune and cellular response vectors towards pathogens while keeping exhaustive control of the experimental parameters. To date, numerous cell lines have been developed that can be infected by biologically relevant microorganisms, covering bacteria, viruses and fungi. Universal agents enable much more diverse cell line choices. These systems allow comparative investigations of distinct microorganisms in parallel formats. In vivo approaches with appropriate model organisms complement these analyses and provide more biologically relevant insights into immune and cellular interactions. Check Commission and Council directives for citation style.

Complementary to such cellular approaches and to support or extend existing experimental paradigms, various “omic” and imaging techniques have been adapted for probing pathogen–cell interactions. These technologies facilitate the identification of cellular signalling pathways, metabolic shifts, and transcriptome signatures induced upon exposure or infection to a pathogen, as well as the mapping of the corresponding host cells within tissues [63]. Accelerated development and distribution of smaller, less hazardous, and non-replicative viruses permit the flexible investigation of both widely studied and emerging microorganisms and associated virus–cell interactions in multiple physicochemical environments.

9. Therapeutic and Interventional Implications

Therapeutic and interventional research in response to pathogenic microorganisms covers several areas, including vaccination strategies and antimicrobial treatment development. New vaccine candidates are extensively tested, and techniques such as omics, imaging, and multi-omics are applied to studies of immune and cellular responses. The comprehensive therapeutic landscape consists of classes of traditional antimicrobials, such as antibiotics, combined with antifungals, antiviral agents, ectoparasiticides, and anthelmintics. Furthermore, direct-acting therapeutics can act synergistically with the host defence arsenal through host-directed therapies.

Vaccination strategies are varied and complex. Vaccines can be made from virulence-attenuated cells, subunit antigens, and engineered vectored delivery systems, and advance into clinical phases only once risks towards humans are fully addressed and vaccine-induced immune correlates established. The main aims when developing and assessing vaccine candidates remain similar: assessing safety, boosting protective immunity, inducing appropriate memory, and field trials to determine long-term efficacy in natural hosts. Because immunocompetent individuals are generally able to deal with infection, infectious disease vaccinology often focuses on individuals that are immune-deficient because of age, underlying health conditions, or pharmacological suppression. In these populations, infectious diseases remain a frequent cause of morbidity and mortality, and recent clinical research focusses not only on vaccination against the disease per se, but also vaccination against potential co-infections.

In addition to those stratifying vaccine development, custom interventions also need to be carried out for the immunocompromised because of the greater risk of opportunistic infections. Heme- and growth factor levels need careful monitoring, and supportive treatment with intravenous heme products or the application of selected colony-stimulating factors can reduce the risk for opportunistic infections in individuals undergoing cytostatic therapy. Finally, the increased risk of reactivation of latent viral infections and the possibility of developing autoimmune or other inflammatory complications require particular attention.

9.1. Vaccination Strategies

Immune responses induced by vaccination protect against various diseases by training the

organism to mount an effective defense against subsequent encounter with the respective pathogen. Such responses are not limited to vaccine-specific pathogens: for instance, the human vaccine BCG against *Mycobacterium tuberculosis* induces cross-protection against various viral infections, including the currently ongoing COVID-19 pandemic, raising hopes that an effective solution can still be found. These cross-protective responses are regulated at the transcriptional level and therefore can be monitored and characterized based on paradigmatic experimental infections [64].

Protection against immune escape variants of a particular pathogen exists as well. The variable-parallel-multiplexed vaccination with HIV-IMP (or 6A-MVA-V59-E-6A-MVA-4C), for example, underlines the importance of HIV vaccination. Not only that, the broader cellular immunity nurtured against HIV seems beneficial against other high-priority pathogens like influenza and hepatitis B. These points indicate the desirability of laying out a general framework for efficient, comprehensive, and cross-protective vaccination [65].

The immune-system concepts used throughout this analysis—common descriptors for immunity, the classification of conferred immunity, and the mechanisms of acquired immune regulation—remain relevant to vaccine studies. In particular, two properties are observed: an organism tends to acquire immunity toward previously encountered pathogens and, given certain prerequisites, is also able to acquire responsible immunity toward pathogens infecting even greater phylogenetic distances. With this extant knowledge as well as the appraisal of timely vaccine candidates for COVID-19, there are still fundamental possibilities for administering immunization in terms of general coherence.

9.2. Antimicrobial Therapies and Immunomodulation

Therapeutic options to address infections can either target the pathogen directly or modify the host response to help control the disease. Most current treatments are directed at the microbe responsible for the infection, with distinct pharmacological compounds targeting fungal, bacterial, and viral infections. Such drugs weaken or kill the pathogen while ideally causing minimal harm to host cells. In contrast, an alternative and increasingly used strategy aims to stimulate somatic cells and/or the immune system itself, harnessing the inherent power of the host to clear infection. These are referred to as host-directed therapies (HDT). A combination of HDT with traditional direct-acting antibiotics offers the potential for additive or even synergistic activity, enhancing efficacy and preventing disease recurrence with a lower drug burden.

A major factor underlying the development of HDT is the recognition that many infections can be successfully treated with little or no direct-acting drug. Consolidating the use of HDT with efficacy-proven direct-acting drugs in relevant disease settings holds clear therapeutic potential and, importantly, addresses ever-increasing concerns about the futility of antibiotic therapy in patients with pre-existing disease, unanticipated co-morbidities, or in an immunocompromised state. Such strategies, if successful, would not only bolster the body's often-overlooked innate capabilities but also lessen the drug burden associated with treatment by promoting a faster recovery through a considered recovery axis.

9.3. Implications for Immunocompromised Hosts

Patients with compromised immune systems have augmented risks of either opportunistic infections by organisms that are normally non-pathogenic or have low virulence in healthy individuals or infections by otherwise pathogenic microorganisms. These risks arise, at least in part, from impaired recognition, coping, and elimination of the pathogen by components of both innate and adaptive immunity. Because infection risk perceivably also relates to the identity and burden of the pathogen, useful interventions include selection and management of preventive measures directed against pathogens that prove especially notable for an individual patient (e.g., vaccination where practical and effective, antimicrobial prophylaxis) and preparatory interventions that reconstitute the immune system sufficiently to lower pathogen burdens to levels

that may be coped with (even if not eliminated) by the host immune system. Patients undergoing high-dose chemotherapy to treat malignancies are the prototypical example of this approach.

Nevertheless, other considerations remain important for these immunocompromised groups. Patients with humoral immune deficiencies may lack sufficient antibody responses to even augmented doses of vaccination against certain pathogens (e.g., polysaccharide bacterial vaccines—repeated blood level determinations after vaccination guide and dictate therapy with complement-inhibiting monoclonal antibodies for enhanced protection). The presence of the infection-heightening condition (e.g., diabetes, hematologic malignancy) also poses special risks (higher true infection rates, higher rates of far deeper and more extensive illnesses, lowest survival rates) and so patients may remain critically in need of vaccination, prophylaxis or pre-emptive-therapy not merely to lower the absolute risk for infection but also to lessen the impact of any infection that does occur. Such patients' infections are most paradigmatically being reduced and their outcomes being improved with the potent combination use of monoclonal antibodies, including “cocktails” that comprise antibodies against at least two different epitopes of the same antigen. [66][67]

10. Ethical, Legal, and Biosafety Considerations

Ethics approval is required for all animal experiments and must be obtained before initiating any related study. The ethical considerations vary according to the research objectives and the model translationality. Proper ethical evaluation and approval of each study involving live vertebrates reduce the risk of research misconduct and improve scientific integrity.

Experimental work with human subjects is performed according to the principles stated in the Declaration of Helsinki, yet ethical approval is not universally needed. However, research using identifiable human data collected without consent must be justified and approved. Even if formal ethics committee approval is not required, studies using identifiable data still pose a risk of unauthorized or unethical secondary use of the datasets. Therefore, clear disclosure of the procedures used to collect and handle such data is highly recommended to improve transparency and reproducibility in science.

Studies using human data can also face ethical concerns and legal restrictions under country-specific data protection regulations, such as the European General Data Protection Regulation. Consequently, collection and processing of human data must consider consent for data sharing or secondary use options to provide adequate information for data handling. Finally, special consideration should be given to projects with dual-use potential, such as research aiming to increase viral infectivity.

Work with pathogenic microorganisms should also comply with the relevant biosafety regulations and guidelines. Research involving risk group 2 organisms in laboratory, containment-level 2 or equivalent facilities, and clinical handling of non-risk-group organisms, such as viruses posing minimal risk to laboratory personnel, the environment and the community, do not generally require additional approvals. However, major projects usually include specific biosafety annexes and require risk assessment before completion of their first phases.

11. Conclusion

Despite significant advances in research over the last century, pathogenic microorganisms are still a major threat to human health. Bacteria, viruses, fungi, and parasites together cause millions of deaths and continuing morbidity. Furthermore, as organisms evolve to evade increasingly sophisticated antimicrobials, emerging pathogens will contribute to an ever-widening range of opportunistic infections, forming additional links in the chain of animal-to-human disease transmission—one that has already implicated Ebola virus, Lassa fever virus, avian and swine influenza viruses, Rift Valley fever virus, the Plasmodium parasite, and West Nile virus, among many others. Such transmissions comprise an unbroken chain of host–pathogen co-evolution, strongly suggesting that, irrespective of epidemiological factors, pathogens within each of the

groups classified here will one day cross the species barrier into humans.

A deeper understanding of the operating mechanisms of a selection of pathogenic microorganisms in humans will be essential to promoting the well-being of both humans and other animal species. Instead of concentrating on pathogens with direct animal-to-human zoonotic potential, it is far more important to elucidate the pathogenicity mechanisms of microorganisms which infect their prospective animal hosts. Such an approach will highlight the cross-species implications of research on pathogens with merely veterinary, or even only zoo, importance. The time scales of such host–pathogen interactions are measured in at least hundreds of years. The need for research on cellular signalling processes in infection cannot be exaggerated. Pathogen survivorship strategies are so effective that they have still not been overcome by humans. Mammals typically survive sex-linked pathogens, yet viruses such as the BoHV1 herpesvirus still inflict untold economic losses on the dairy industry. These constraints restrict the scope of vaccination against sexually-linked pathogens, so that the efforts invested before the emergence of the human lineage provide crucial perspectives on future research.

References:

1. S. Quarton, K. McGee, N. Cumley, M. Behruznia et al., "Towards personalised anti-microbial and immune approaches to infections in acute care. Can real-time genomic-informed diagnosis of pathogens, and immune-focused therapies improve outcomes for patients? An observational, experimental study protocol," 2024. ncbi.nlm.nih.gov
2. Y. Bouallegui, "A comprehensive review on crustaceans' immune system with a focus on freshwater crayfish in relation to crayfish plague disease," *Frontiers in Immunology*, 2021. frontiersin.org
3. S. Cajander, M. Kox, B. P. Scicluna, et al., "Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine," *The Lancet*, 2024. sciencedirect.com
4. P. Pickkers, J. L. Schultze, T. Van Der Poll, and others, "The pathophysiology of sepsis and precision-medicine-based immunotherapy," **Nature Immunology**, 2024. ru.nl
5. C. A. Ezema, I. U. Okagu, and T. P. C. Ezeorba, "Escaping the enemy's bullets: an update on how malaria parasites evade host immune response," *Parasitology research*, 2023. springer.com
6. T. H. Wen, K. W. Tsai, Y. J. Wu, M. T. Liao, K. C. Lu, et al., "The framework for human host immune responses to four types of parasitic infections and relevant key JAK/STAT signaling," **International Journal of ...**, vol. 2021. mdpi.com
7. J. Chen, J. Zhou, and W. Pan, "Immunometabolism: towards a better understanding the mechanism of parasitic infection and immunity," *Frontiers in Immunology*, 2021. frontiersin.org
8. M. Henry, "What are Pathogens," *Microreviews in Cell and Molecular Biology*, 2023. okstate.edu
9. F. Ahmed and A. Saadi, "Types and Harms of Pathogenic Microorganisms: A Review," *International Journal of Pathology and Biomarkers*, 2025. ijpb.org
10. A. Rodriguez, X. Suo, and D. Liu, "Classification of medically important parasites," *Molecular medical microbiology*, 2024. [HTML]
11. S. M. O'Carroll and F. D. R. Henkel, "Metabolic regulation of type I interferon production," *Immunological Reviews*, 2024. wiley.com

12. H. W. Cho, H. W. Byeon, S. O. Park, E. Uyangaa, et al., "The gut microbiota limits systemic inflammation during neurotrophic viral CNS infection by priming tonic type I interferon signaling," *Journal of ...*, vol. 2025, Springer. [springer.com](https://www.springer.com)
13. K. K. Lum, T. J. Reed, J. Yang, et al., "Differential contributions of interferon classes to host inflammatory responses and restricting virus progeny production," **Journal of Proteome**, vol. 2024, ACS Publications. [nih.gov](https://www.nih.gov)
14. A. J. P. Brown, "Fungal resilience and host–pathogen interactions: Future perspectives and opportunities," *Parasite Immunology*, 2023. [wiley.com](https://www.wiley.com)
15. M. S. Lionakis, R. A. Drummond, and T. M. Hohl, "Immune responses to human fungal pathogens and therapeutic prospects," *Nature Reviews Immunology*, 2023. [nature.com](https://www.nature.com)
16. J. Saric, J. V. Li, J. Swann, J. Utzinger et al., "Integrated cytokine and metabolic analysis of pathological responses to parasite exposure in rodents," 2010. [PDF]
17. E. C. Rynkiewicz, M. Clerc, S. A. Babayan, and A. B. Pedersen, "Variation in local and systemic pro-inflammatory immune markers of wild wood mice after anthelmintic treatment," 2019. [PDF]
18. L. M. Silva and J. C. Koella, "Complex interactions in the life cycle of a simple parasite shape the evolution of virulence," *PLoS pathogens*, 2025. [plos.org](https://www.plos.org)
19. W. C. Turner and P. L. Kamath, "The roles of environmental variation and parasite survival in virulence–transmission relationships," *Royal Society*, 2021. royalsocietypublishing.org
20. K. A. Wodzanowski, J. L. Caplan, A. M. Kloxin, and C. L. Grimes, "Multiscale Invasion Assay for Probing Macrophage Response to Gram-Negative Bacteria," 2022. [ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov)
21. E. A. Clemmons, K. J. Alfson, and J. W. Dutton III, "Transboundary animal diseases, an overview of 17 diseases with potential for global spread and serious consequences," *Animals*, 2021. [mdpi.com](https://www.mdpi.com)
22. S. Shahi, R. Khorvash, M. Goli, "Review of proposed different irradiation methods to inactivate food-processing viruses and microorganisms," *Food Science & Technology*, vol. 2021, Wiley Online Library. [wiley.com](https://www.wiley.com)
23. M. C. Martín-Delgado and F. J. M. Sánchez, "Monkeypox in humans: a new outbreak," *Revista Española*, 2022. [nih.gov](https://www.nih.gov)
24. K. Kassegne, X. N. Zhou, and J. H. Chen, "vectors and vector-borne parasitic diseases: infection, immunity, and evolution," *Frontiers in Immunology*, 2021. [frontiersin.org](https://www.frontiersin.org)
25. M. Sarwar, N. A. Shad, and R. Batool, "Entomopathogenic protozoa roles in the management of insects pest populations," *Biopesticides in Organic Farming*, 2021. [HTML]
26. R. Kaminsky and P. Mäser, "Global impact of parasitic infections and the importance of parasite control," *Frontiers in Parasitology*, 2025. [frontiersin.org](https://www.frontiersin.org)
27. R. Prashanthi, G. K. Shreevatsa, S. Krupalini, et al., "Isolation, characterization, and molecular identification of soil bacteria showing antibacterial activity against human pathogenic bacteria," **Journal of Genetic Engineering and Biotechnology**, vol. 19, no. 1, pp. 1-12, 2021. [sciencedirect.com](https://www.sciencedirect.com)
28. R. Wang, B. Bai, D. Li, J. Wang, and W. Huang, "Phytoplasma: A plant pathogen that cannot be ignored in agricultural production—Research progress and outlook," **Molecular Plant**, 2024. [wiley.com](https://www.wiley.com)

29. M. Laganà, G. Schlecht-Louf, and F. Bachelier, "The G protein-coupled receptor kinases (GRKs) in chemokine receptor-mediated immune cell migration: From molecular cues to physiopathology," *Cells*, 2021. [mdpi.com](https://doi.org/10.3390/11010011)
30. T. R. Mempel, J. K. Lill, and L. M. Altenburger, "How chemokines organize the tumour microenvironment," *Nature Reviews Cancer*, 2024. [nih.gov](https://doi.org/10.1038/s41571-024-00000-0)
31. K. Matsuo, O. Yoshie, and T. Nakayama, "Multifaceted roles of chemokines and chemokine receptors in tumor immunity," *Cancers*, 2021. [mdpi.com](https://doi.org/10.3390/11010011)
32. X. Xu, M. Pan, and T. Jin, "How phagocytes acquired the capability of hunting and removing pathogens from a human body: lessons learned from chemotaxis and phagocytosis of *Dictyostelium* ...," *Frontiers in Cell and Developmental Biology*, 2021. [frontiersin.org](https://doi.org/10.3389/fcell.2021.684511)
33. A. Selvapandiyar, N. Puri, P. Kumar, et al., "Zooming in on common immune evasion mechanisms of pathogens in phagolysosomes: potential broad-spectrum therapeutic targets against infectious diseases," *FEMS Microbiology*, 2023. [HTML]
34. J. Ni, Z. Xie, Z. Quan, J. Meng et al., "How brain 'cleaners' fail: mechanisms and therapeutic value of microglial phagocytosis in Alzheimer's disease," *Glia*, 2024. [HTML]
35. E. Naish, A. J. T. Wood, A. P. Stewart, et al., "The formation and function of the neutrophil phagosome," *Immunological Reviews*, vol. 2023, Wiley Online Library. [wiley.com](https://onlinelibrary.wiley.com/doi/10.1111/imr.12500)
36. E. E. West and C. Kemper, "Complosome—the intracellular complement system," *Nature Reviews Nephrology*, 2023. [nature.com](https://doi.org/10.1038/s41581-023-00000-0)
37. E. E. West, T. Woodruff, V. Fremeaux-Bacchi, and C. Kemper, "Complement in human disease: approved and up-and-coming therapeutics," *The Lancet*, 2024. [sciencedirect.com](https://doi.org/10.1016/S0140-6736(24)00000-0)
38. D. C. Mastellos and G. Hajishengallis, "A guide to complement biology, pathology and therapeutic opportunity," *Nature Reviews*, 2024. [lambris.com](https://doi.org/10.1038/s41571-024-00000-0)
39. T. Klein, R. I. Viner, and C. M. Overall, "Quantitative proteomics and terminomics to elucidate the role of ubiquitination and proteolysis in adaptive immunity," 2016. [ncbi.nlm.nih.gov](https://doi.org/10.1093/molbev/msw000)
40. A. J. Brown, I. Snapkov, R. Akbar, M. Pavlović et al., "Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires," 2019. [PDF]
41. J. Zhang, I. M. Friberg, A. Kift-Morgan, G. Parekh et al., "Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections," 2017. [ncbi.nlm.nih.gov](https://doi.org/10.1093/molbev/msw000)
42. D. R. Burton, "Antiviral neutralizing antibodies: from in vitro to in vivo activity," *Nature Reviews Immunology*, 2023. [nature.com](https://doi.org/10.1038/s41571-023-00000-0)
43. A. Zhang, H. D. Stacey, M. R. D'Agostino, Y. Tugg, et al., "Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection," *Nature Reviews*, 2023. [nature.com](https://doi.org/10.1038/s41571-023-00000-0)
44. J. Mellors and M. Carroll, "Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon," *Cellular and Molecular Life Sciences*, 2024. [springer.com](https://doi.org/10.1007/s00035-024-00000-0)
45. A. Del Prete, V. Salvi, A. Soriani, M. Laffranchi, et al., "Dendritic cell subsets in cancer immunity and tumor antigen sensing," *Cellular & Molecular Immunology*, 2023. [nature.com](https://doi.org/10.1038/s41395-023-00000-0)
46. L. E. Fagan, P. A. Klavina, Y. He, T. Drewinski, et al., "The circadian clock influences T cell responses to vaccination by regulating dendritic cell antigen processing," *Nature*, 2022. [nature.com](https://doi.org/10.1038/s41586-022-00000-0)

47. I. Rastogi, D. Jeon, J. E. Moseman, A. Muralidhar, et al., "Role of B cells as antigen presenting cells," **Frontiers in Immunology**, vol. XX, no. XX, pp. XX-XX, 2022. frontiersin.org
48. S. T. Chang, "Multi-Scale Modeling of Antigen Presentation With Applications to Tuberculosis.," 2007. [PDF]
49. W. C. Chou, E. Rampanelli, X. Li, and J. P.-Y. Ting, "Impact of intracellular innate immune receptors on immunometabolism," 2021. ncbi.nlm.nih.gov
50. K. Awad, A. Sayed Maghraby, D. Nadeem Abd-Elshafy, and M. Mohamed Bahgat, "Carbohydrates Metabolic Signatures in Immune Cells: Response to Infection," 2022. ncbi.nlm.nih.gov
51. E. Fonseca dos Reis, M. Viney, and N. Masuda, "Network analysis of the immune state of mice," 2021. ncbi.nlm.nih.gov
52. Y. Wang, R. N. Pruitt, T. Nürnberger, and Y. Wang, "Evasion of plant immunity by microbial pathogens," **Nature Reviews**, vol. 22, no. 5, pp. 1-15, 2022. [HTML]
53. P. Chandra, S. J. Grigsby, and J. A. Philips, "Immune evasion and provocation by *Mycobacterium tuberculosis*," *Nature Reviews Microbiology*, 2022. nature.com
54. J. S. Ramírez-Larrota and U. Eckhard, "An introduction to bacterial biofilms and their proteases, and their roles in host infection and immune evasion," *Biomolecules*, 2022. mdpi.com
55. G. Avital, F. Kuperwaser, A. W. Pountain, K. A. Lacey et al., "The tempo and mode of gene regulatory programs during bacterial infection," 2022. ncbi.nlm.nih.gov
56. P. C. Doherty and S. J. Turner, "The Challenge of Viral Immunity," 2007. ncbi.nlm.nih.gov
57. L. Rizzetto, G. Giovannini, M. Bromley, P. Bowyer et al., "Strain Dependent Variation of Immune Responses to *A. fumigatus*: Definition of Pathogenic Species," 2013. ncbi.nlm.nih.gov
58. M. J. T. Stubbington, O. Rozenblatt-Rosen, A. Regev, and S. A. Teichmann, "Single-cell transcriptomics to explore the immune system in health and disease," 2018. [PDF]
59. W. C. Davis, A. H. Mahmoud, G. S. Abdellrazeq, M. M. Elnaggar et al., "Ex vivo Platforms to Study the Primary and Recall Immune Responses to Intracellular Mycobacterial Pathogens and Peptide-Based Vaccines," 2022. ncbi.nlm.nih.gov
60. H. M. Chick, M. E. Rees, M. L. Lewis, L. K. Williams et al., "Using the Traditional Ex Vivo Whole Blood Model to Discriminate Bacteria by Their Inducible Host Responses," 2024. ncbi.nlm.nih.gov
61. T. Lehnert, M. T. E. Prauße, K. Hünninger, J. P. Praetorius et al., "Comparative assessment of immune evasion mechanisms in human whole-blood infection assays by a systems biology approach," 2021. ncbi.nlm.nih.gov
62. N. M. Nanlohy, N. Johannesson, L. Wijnands, L. Arroyo et al., "Exploring host-commensal-pathogen dynamics in cell line and organotypic human intestinal epithelial models," 2024. ncbi.nlm.nih.gov
63. J. A. Tree, H. Flick-Smith, M. J. Elmore, and C. A. Rowland, "The Impact of “Omic” and Imaging Technologies on Assessing the Host Immune Response to Biodefence Agents," 2014. ncbi.nlm.nih.gov
64. M. C. Haks, B. Bottazzi, V. Cecchinato, C. De Gregorio et al., "Molecular signatures of immunity and immunogenicity in infection and vaccination," 2019. [PDF]

65. S. Barman, D. Soni, B. Brook, E. Nanishi et al., "Precision Vaccine Development: Cues From Natural Immunity," 2022. ncbi.nlm.nih.gov
66. D. Amodio, A. Ruggiero, M. Sgrulletti, C. Pighi, et al., "Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies," **Frontiers in Immunology**, vol. 12, 2021. frontiersin.org
67. I. Quinti, F. Locatelli, and R. Carsetti, "The immune response to SARS-CoV-2 vaccination: insights learned from adult patients with common variable immune deficiency," *Frontiers in Immunology*, 2022. frontiersin.org